Editorial: The COVID-19 vaccine is a gift from science. Accept it
In three separate announcements in recent weeks, three scientific teams at different pharmaceutical companies have given a weary, frightened world what it needs: a verifiable path to defeat the coronavirus pandemic, end the suffering and start the process of returning life to the normal rhythms of “before.”Imagine again going to work and school, to restaurants and concerts without significant risk of infection. Imagine being able to travel. Imagine hugging family members and friends. We are likely to get there in 2021 because a safe, effective COVID-19 vaccine appears on pace for emergency reg...
FDA gives emergency authorization to most precise coronavirus-antibody test yet
NEW YORK — A new, next-level coronavirus-antibody test that measures not just antibodies’ presence but also how much protection they afford are on the way.The test, which on Wednesday received emergency-use authorization from the U.S. Food and Drug Administration, measures the number of neutralizing antibodies that the body’s immune system has produced after exposure, reported CNBC. While previous tests have measured antibody levels, this one zeroes in on the antibodies that attack two specific aspects of the novel coronavirus.This “new generation” of test, the COVID-SeroKlir, was developed by...
New York Daily News
UPS boosts dry ice capabilities in preparation for vaccine transport
UPS said it has boosted its dry ice production capabilities in preparation for the task of distributing COVID-19 vaccines that must be kept at freezing temperatures.As the logistics industry prepares to ship vaccines around the world, experts have raised concerns about a potential dry ice shortage.UPS said it can now produce as much as 1,200 pounds of dry ice per hour at its U.S. facilities.The company said the boosted capacity will ensure there’s enough dry ice to pack shipments from its health care facilities in Louisville, Kentucky and Dallas, Texas, as well as Ontario, Canada.UPS is also p...
The Atlanta Journal-Constitution
Ford aims to offer COVID-19 vaccines to employees, orders ultra-cold freezers
DETROIT — In an attempt to keep the fast-spreading coronavirus pandemic from again disrupting its operations, Ford Motor Co. has ordered a dozen ultra-cold freezers to store vaccines globally when they become available, the company confirmed Tuesday.“It’s important to Ford because the health and safety of our employees is our top priority,” Kelli Felker, Ford global manufacturing and labor communications manager, told the Free Press. “What we’ve done is order these ultra-cold freezers so we can make the vaccine available to them on a voluntary basis when the vaccine is available.”At this point...
Detroit Free Press
AstraZeneca Executive On Positive Covid-19 Vaccine Results
First on CNBC: CNBC Transcript: Dr. Ruud Dobber, President of AstraZeneca US and EVP of BioPharmaceuticals, speaks with CNBC’s “Squawk Box” today explaining their positive Covid vaccine results.Q3 2020 hedge fund letters, conferences and moreAstraZeneca executive explains positive Covid vaccine resultsMEG TIRRELL: So guys, we're going to switch directions right now and bring in Ruud Dobber who is the head of AstraZeneca’s U.S. business and Executive Vice President of Biopharmaceuticals to talk about AstraZeneca and Oxford's vaccine results this morning. Dr. Dobber, thank you for being with us ...
Why a coronavirus vaccine might not get things back to normal
SEATTLE — Coronavirus infections are climbing to record highs nationwide. Patients are filling hospitals in some states. Experts fear we’re in for a dark winter.A shot of hope could be coming, as vaccine makers are deep in clinical trials. Governments are stockpiling doses and preparing for efficient delivery of a vaccine, should one be proven safe and effective.But over time, the stiffest challenge when it comes to vaccines may not be creating, approving or distributing them. It might be getting people to take them.Americans’ willingness to be vaccinated dropped over the summer, with about ha...
The Seattle Times
Dow Jones soars amid news of 90% effective COVID-19 vaccine candidate
So much for watching your 401(k)s go to hell, as President Donald Trump famously suggested would happen if Democrat Joe Biden won the race for the White House.Not so on Monday, anyway.On Monday, Wall Street bet on the odds that America could indeed get back to work — and back into the gym or mall — if an effective vaccine to fight COVID-19 is discovered.The Dow Jones Industrial Average soared by 4.47% — gaining 1,266.06 points — to trade at 29,589.46 points shortly after 10 a.m., a half an hour after the market opened in New York. The Dow was trading at record levels.Shortly before 11:30 a.m.,...
Detroit Free Press
Why vaccine hesitancy is growing during a deadly pandemic
SAN JOSE, Calif. — We’re all desperate for a magic bullet that will restore our pre-COVID lives.But even some of science’s most ardent fans say they’re reluctant to roll up their sleeves and participate in the pandemic’s first wave of inoculations, unnerved by reports of a rushed timetable, politicization and poor communication.There isn’t a vaccine yet — and with initial supplies very limited, such apprehension may not pose an immediate problem, say experts. But persistent distrust could spell trouble for the nation’s ambitious Operation Warp Speed campaign to protect all Americans.These aren...
The Mercury News
Once a COVID-19 vaccine is here, there will be a new challenge: convincing people it's safe
PHILADELPHIA — There’s a good chance that a coronavirus vaccine could be available by late 2020 or early 2021.Developing an effective vaccine that fast would be a remarkable scientific achievement. It would also provide the first real hope of taming a new, deadly virus that has upended all aspects of American life — if people are willing to take it. Many may not be.Polls show decreasing support for getting vaccinated as battles between science and politics have weakened trust in government agencies that evaluate and recommend vaccines. Enthusiasm for a vaccine is particularly low among Black A...
The Philadelphia Inquirer
Nation and world news briefs
US-run clinical trial of Eli Lilly antibody therapy to endEli Lilly & Co. said a clinical trial of its experimental antibody therapy in hospitalized COVID-19 patients will end, after the U.S. government-run study was paused earlier this month.The company said in a statement that the decision was based on data suggesting the treatment is unlikely to help hospitalized COVID-19 patients recover from the advanced stage of their disease.On Oct. 14, the Indianapolis drug giant said enrollment had been paused in the so-called ACTIV-3 trial of its neutralizing monoclonal antibody treatment sponsored b...
Tribune News Service